Skip to main content

Advertisement

SpringerLink
Log in

Relationship between serum IL-18 and VEGF levels in patients with prostate cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of our study was to analyze interleukin-18 (IL-18) and vascular endothelial growth factor (VEGF) serum levels in patients with prostate cancer before and after operation and the possible correlation between IL-18 and VEGF serum levels.

Methods

Serum IL-18 and VEGF levels were measured by enzyme-linked immunosorbent assay (ELISA) in 36 patients with prostate cancer before and after radical prostatectomy and in 25 healthy controls.

Results

Serum IL-18 and VEGF levels were significantly higher in patients with prostate cancer before operation with respect to healthy controls (P < 0.05), with a highly significant correlation between IL-18 and VEGF (R = 0.800, P = 0.017). It was significantly reduced in IL-18 and VEGF after operation. IL-18 and VEGF serum concentrations were correlated with the clinicalopathological status of patients with prostate cancer.

Conclusion

It is correlative with serum IL-18 and VEGF. Serum IL-18 and VEGF levels may be useful prognostic marker in patients with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cristi E, Perrone G, Toscano G, et al. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol, 2005, 58: 1170–1174.

    Article  CAS  PubMed  Google Scholar 

  2. Mendoza L, Valcarcel M, Carrascal T, et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma etastasis. Cancer Res, 2004, 6: 304–310.

    Article  Google Scholar 

  3. Balkow S, Loser K, Krummen M, et al. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol, 2009, 18:78–87.

    Article  CAS  PubMed  Google Scholar 

  4. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 2007, 4: 329–335.

    CAS  PubMed  Google Scholar 

  5. Khatri A, Husaini Y, Ow K, et al. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009, 15: 2323–2334.

    Article  CAS  PubMed  Google Scholar 

  6. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology, 2006, 68:244–248.

    Article  PubMed  Google Scholar 

  7. Kaushal V, Mukunyadzi P, Dennis RA, et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res, 2005, 11: 584–593.

    CAS  PubMed  Google Scholar 

  8. Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis, 2010, 13: 43–58.

    Article  CAS  PubMed  Google Scholar 

  9. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol, 2001, 19: 1207–1225.

    CAS  PubMed  Google Scholar 

  10. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology, 1999, 53: 302–307.

    Article  CAS  PubMed  Google Scholar 

  11. Werther K, Christensen IJ, Nielsen HJ, et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer, 2002, 86: 417–423.

    Article  CAS  PubMed  Google Scholar 

  12. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg, 2002, 236: 37–42.

    Article  PubMed  Google Scholar 

  13. Teknos TN, Cox C, Yoo S, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck, 2002, 24: 1004–1011.

    Article  PubMed  Google Scholar 

  14. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res, 2002, 8: 3193–3197.

    CAS  PubMed  Google Scholar 

  15. Catena R, Muniz-Medina V, Moralejo B, et al. Increased expression of VEGF 121/VEGF 165–189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Inter J Cancer, 2007, 120: 2096–2109.

    Article  CAS  Google Scholar 

  16. Kang JS, Bae SY, Kim HR, et al. nterleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 2009, 30: 1987–1996.

    Article  CAS  PubMed  Google Scholar 

  17. Khalili-Azad T, Razmkhah M, Ghiam AF, et al. Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 2009, 56: 22–25.

    Article  CAS  PubMed  Google Scholar 

  18. Samsami Dehaghani A, Shahriary K, Kashef MA, et al. Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 2009, 36: 2393–2397.

    Article  CAS  PubMed  Google Scholar 

  19. Perrella O, Cuomo O, Sbreglia C, et al. IL-18 and Interferon-gamma in HCV-related hepatocellular carcinoma: a model of interplay between immune status and cancer. J Biol Regul Homeost Agents, 2009, 23: 251–258.

    CAS  PubMed  Google Scholar 

  20. Shaojun N, Duangai W, Caibin F, et al. Clinical value of serum interleukin-18 in patients with prostate cancer. Chinese-German J Clin Oncol, 2007, 6: 574–578.

    Article  Google Scholar 

  21. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterology, 2006, 12: 4473–4477.

    CAS  Google Scholar 

  22. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res, 1996, 2: 821–826.

    CAS  PubMed  Google Scholar 

  23. Hicklin DJ. Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005, 23:1011–1027.

    Article  CAS  PubMed  Google Scholar 

  24. Li H, Kantoff PW, Ma J, et al. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2005, 14:1 557–1561.

    CAS  Google Scholar 

  25. Peyromaure M, Goulvestre C, Fulla Y, et al. Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer. Urology, 2005, 66: 687–691.

    Article  PubMed  Google Scholar 

  26. Miyake H, Muramaki M, Kurahashi T, et al. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol, 2010, 28: 145–151.

    CAS  PubMed  Google Scholar 

  27. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther, 2009, 8: 2286–2296.

    Article  PubMed  Google Scholar 

  28. Wong SY, Haack H, Crowley D, et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res, 2005, 65: 9789–9798.

    Article  CAS  PubMed  Google Scholar 

  29. Kitagawa Y, Dai J, Zhang J, et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res, 2005, 65: 10921–10929.

    Article  CAS  PubMed  Google Scholar 

  30. Han MY, Zheng S, Yu JM, et al. Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ (Science), 2004, 5: 472–476.

    Article  CAS  Google Scholar 

  31. Park CC, Morel JC, Amin MA, et al. Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 2001, 167: 1644–1653.

    CAS  PubMed  Google Scholar 

  32. Cao R, Farnebo J, Kurimoto M, et al. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J, 1999, 13: 2195–2202.

    CAS  PubMed  Google Scholar 

  33. Jablonska E, Puzewska W, Grabowska Z, et al. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokines, 2005, 30: 93–99.

    Article  CAS  Google Scholar 

  34. Crohns M, Saarelainen S, Laine S, et al. Poussa, Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. Cytokine, 2010, 50: 30–36.

    Article  CAS  PubMed  Google Scholar 

  35. Morel JC, Park CC, Zhu K, et al. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chemistry, 2002, 277: 34679–34691.

    Article  CAS  Google Scholar 

  36. Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunology Lett, 2006, 103: 159–166.

    Article  CAS  Google Scholar 

  37. Lee JK, Kim SH, Lewis EC, et al. Differences in signaling pathways by IL-1beta and IL-18. Proc Nat Acad Sci U S A, 2004, 101: 8815–8820.

    Article  CAS  Google Scholar 

  38. Nakahira M, Ahn HJ, Park WR, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by upregulating the binding activity of IL-18-induced activator protein 1. J Immunol, 2002, 168: 1146–1153.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urological Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, China

    Shaojun Nong, Yueping Zhang, Shujun Zhou, Wenguang Li, Limin Ma & You Wu

Authors
  1. Shaojun Nong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yueping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shujun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenguang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Limin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. You Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yueping Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nong, S., Zhang, Y., Zhou, S. et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer. Chin. -Ger. J. Clin. Oncol. 9, 643–647 (2010). https://doi.org/10.1007/s10330-010-0702-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-010-0702-6

Key words

Search

Navigation